Document:

<PAGE>

                                                                   Exhibit 10.55

                         DOUGLAS PHARMACEUTICALS LIMITED

                     DEVELOPMENT AND DISTRIBUTION AGREEMENT
                  Distribution of Senetek's Product by Douglas

PARTIES

DOUGLAS PHARMACEUTICALS LIMITED ("DOUGLAS")

SENETEK PLC ("SENETEK")

          Senetek and Douglas have agreed that together they will develop the
          market in New Zealand for the Product and that Douglas shall have the
          exclusive right to distribute the Product in New Zealand with the
          right of first offer to distribute the Product in Australia in
          accordance with the terms set out in this agreement (including the
          attached Terms and Conditions).

          Senetek have agreed to pay Douglas for its assistance to develop
          packaging of the Product which packaging shall be used by Senetek
          worldwide.

          The parties agree to be bound by the terms of this agreement
          (including the attached Terms and Conditions).

SENETEK

POSTAL ADDRESS             620 Airpark Road, Napa, CA 94558

STREET ADDRESS             620 Airpark Road, Napa, CA 94558

TELEPHONE NO               1 707226 3900          FACSIMILE NO 1 707259 6238

CONTACT PERSON             Andreas Tobler

DOUGLAS

POSTAL ADDRESS             PO Box 45027, Auckland 8

STREET ADDRESS             Central Park Drive, Lincoln, Auckland

TELEPHONE NO               00649 835 0660         FACSIMILE NO 00649 835 0665

CONTACT PERSON             Michael Sierrnans

<PAGE>

                     DEVELOPMENT AND DISTRIBUTION AGREEMENT

        PRODUCT                                                  TRADE MARKS

Invicorp 2 (1)                                           InvicorpTM

(1) consisting of:

       a. one ampoule of Invicorp 2
       b. one syringe
       c. one 21g needle
       d. one 30g needle

       (a) to (d) together also called a "Unit of Product".

<PAGE>

Confidential Treatment Requested
--------------------------------

COMMENCEMENT DATE                  12 November 2002
                                   ("Commencement Date")

TERRITORY                          New Zealand
                                   together with any other countries or regions
                                   that the parties may agree shall be included
                                   in the territory from time to time by
                                   agreement in writing ("Territory")

TERMS OF DELIVERY                  The Units of Product shall be airfreighted
                                   CIP under Cold Chain conditions and delivered
                                   to the address specified by Douglas

                                   (CIP as that term is defined in the Incoterms
                                   published by the International Chamber of
                                   Commerce, as amended from time to time).

TERM OF APPOINTMENT                Three years
                                   ("Term")

RENEWAL TERMS                      Upon the expiry of the Term, this agreement
                                   shall automatically be renewed for further
                                   consecutive periods of two years, subject to
                                   either party giving notice in writing at
                                   least six (6) months prior to the expiry of
                                   the relevant Term that it does not wish to
                                   renew the agreement.

PRICE AND PAYMENT TERMS            (I) Senetek shall pay to Douglas no more than
                                   [***] 11- II for services to be provided by
                                   Douglas in assisting Senetek to develop
                                   Product packaging to be used by Senetek in
                                   the sale and distribution of the Product
                                   worldwide.

                                   The payment by Senetek shall be made within
                                   30 days of the invoice date in accordance
                                   with the following timetable:

                                   (a) [***] to be paid on the Commencement
                                       Date;

                                   (b) [***] to be paid on the first commercial
                                       sale of the Product within the Territory;

                                   (c) The balance to be charged as incurred by
                                       Douglas at cost.

                    (2)            Douglas shall pay to Senetek [***] of the
                                   total Net Selling Price received by Douglas
                                   for the Net Sales of the Product within the
                                   Territory.

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

<PAGE>

                                   Douglas shall pay Senetek within 30 days of
                                   the end of each calendar quarter in respect
                                   of sales of Product during that previous
                                   calendar quarter. A statement setting forth
                                   in reasonable detail the basis for the
                                   calculation of the amount owing to Senetek
                                   for the relevant calendar quarter shall
                                   accompany each payment.

EXECUTION
DOUGLAS PHARMACEUTICALS                      SENETEK PLC
LIMITED                                      by:
by:

--------------------------------             --------------------------------
Signature                                    Signature

--------------------------------             --------------------------------
Name (G. Douglas)                            Name  (Andreas Tobler)

--------------------------------             --------------------------------
Position (Managing Director)                 Position (COO & MD Europe)

<PAGE>

Confidential Treatment Requested
--------------------------------

                              TERMS AND CONDITIONS

1.  INTERPRETATION

1.1       In these Terms and Conditions:

          "Net Sales" means the actual bona fide third party sales of the
          Product made by Douglas as per invoices covering the sales less all
          rebates, returns, trade and cash discounts and all taxes.

          "Net Selling Price" means the sales price established by Senetek for
          each Unit of Product, which price shall be at least [***] higher than
          the price for which Pharmacia's Caverject product is sold in the
          Territory.

          "Product" means the Product described at the front of this agreement,
          together with any additional Product which Douglas agrees to
          distribute pursuant to clause 5.3.

          "Trade Marks" means the trade marks described at the front of this
          agreement (as amended from time to time as a consequence of any new
          Product being added to the list of Products pursuant to clause 5.3)
          and/or such other trade marks used by Senetek during the Term in
          connection with the Product.

          All other capitalised terms shall have the meaning given to them at
          the front of this agreement.

1.2       Interpretation: In this agreement, unless the context otherwise
          requires:

          (a)  the singular includes the plural and vice versa;

          (b)  references to clauses and schedules are references to clauses and
               schedules in this agreement;

          (c)  section and clause headings have been inserted for convenience
               only and shall not affect the interpretation of this agreement;
               and

          (d)  references to any statute shall include any modification or
               re-enactment of the statute and all legislation, orders and
               regulations issued under that statute or passed or made in
               substitution for the same.

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

<PAGE>

2.  TERM OF APPOINTMENT

2.1       Term of appointment: This agreement shall commence on the Commencement
          Date and shall continue for the Term specified at the front of this
          agreement (unless sooner terminated under section 16).

2.2       Renewal: Any rights of renewal shall be as specified at the front of
          this agreement, subject to there being no prior breach of this
          agreement and the parties having complied with their respective
          obligations under this agreement.

3.  DOUGLAS' OBLIGATIONS

3.1       Douglas' obligations: Douglas shall at all times during the Term use
          its reasonable efforts to fully develop and exploit the potential
          market for the Product and to distribute, sell and promote, the
          Product in its original form under the Trade Marks. In particular,
          Douglas shall:

          (a)  provide all of its sales representatives with ongoing training
               and support (or arrange for the provision of the same by a
               suitably qualified person) to assist them in promoting the
               Product;

          (b)  store sufficient stock of the Product under conditions that
               prevent deterioration (whether due to temperature, humidity, dust
               or other environmental factors) before the specified expiry date;

          (c)  allow Senetek to visit any premises at which Douglas stores
               and/or packages Product during business hours for inspection
               purposes, provided that Senetek shall be required to give
               reasonable notice of any such proposed inspection visit;

          (d)  notify Senetek of any known or suspected infringement of Senetek'
               rights in the Product in accordance with section 13;

          (e)  use its reasonable efforts to gain government cost reimbursement
               for the Product;

          (f)  market the Autoject 2 auto injector in combination with the
               Product if Senetek so requires.

          In addition to the above obligations, Douglas shall assist Senetek to
          develop packaging and labelling for the Product to be used by Senetek.

3.2       Trade Marks: Douglas must conform to all reasonable requirements of
          Senetek in relation to the use of the Trade Marks on the Product and
          packaging and in all advertising.

3.3       No alterations: Douglas shall not, without Senetek's prior written
          consent, alter, or add to, or apply or attach anything to, the Product
          or their packaging or labelling.

3.4       Compliance with laws: Douglas must observe and comply with all
          statutes, regulations, by-laws, requirements and directions of any
          national or local authority in the Territory having jurisdiction in

<PAGE>

          relation to the promotion and distribution of the Product and the
          performance of any of its obligations under this agreement.

3.5       Promotional activities: Douglas shall apply at least the same
          marketing and promotional activities, expenditures and sales force in
          the Territory as are customary for the sale of like products. Douglas
          shall, in cooperation with Senetek and with Senetek's approval,
          develop promotional documentation, brochures and other materials
          relating to the Product in sufficient quantities to enable Douglas to
          fully promote the Product in the Territory. Senetek shall have the
          right to use the promotional documentation, brochures and other
          materials relating to the Product for promotional activities in other
          countries. The cost of such promotional documentation, brochures and
          other materials shall be borne by Douglas.

3.6       Audits: Douglas shall at the request of Senetek allow independent
          auditors reasonable access to the data necessary to audit the
          calculation of the total Net Selling Price and Net Sales in any
          calendar year. Any such audit shall be commenced by the designated
          auditors no later than three months following the end of the relevant
          calendar year and not more than one audit shall be conducted during
          any calendar year. Senetek shall pay the costs of such independent
          audit unless the audit finds that Douglas' calculation of total Net
          Selling Price and Net Sales in any calendar year was understated by
          more than 5% from the calculations arrived at by the audit.

4.  OBLIGATIONS OF SENETEK

4.1       Information: Senetek shall provide Douglas with all technical and
          marketing information and assistance as Douglas may from time to time
          consider necessary to enable Douglas to perform its obligations under,
          and obtain the full benefit of, this agreement including, without
          limitation, information regarding new developments of the Product.

4.2       Sufficient stocks: Senetek shall ensure that Douglas has access at all
          times to sufficient stocks of each of the Product to enable Douglas to
          meet its obligations under, and obtain the full benefit of, this
          agreement.

4.3       Promotional activities: Senetek shall supply Douglas and its employees
          with an agreed number of samples of the Product. The parties have
          agreed that Douglas shall provide with each two Units of Product sold
          one free Unit of Product.

5.  PRODUCT

5.1       Bulk packaging: Senetek shall ship the Product in bulk pursuant to the
          terms of delivery set forth at the front of this agreement. Douglas
          shall package and label the Product in the Territory free of charge,
          provided that Douglas shall:

          (a)  submit to Senetek in advance for its approval (such approval not
               to be unreasonably withheld) all packaging and labelling used in
               the repackaging; and

          (b)  provide Senetek with samples of packaged and labelled Product on
               request.

<PAGE>

          (c)  The Product shall carry Senetek's name with fine print stating
               "distributed by Douglas" on the packaging.

5.2       Cost of packaging: Senetek shall pay cost price for all packaging and
          labelling materials used by Douglas to package the Product. Douglas
          shall provide, if requested by Senetek copies of all invoices for such
          materials.

5.3       First right of offer: During the Term hereof, Douglas shall have the
          right of first offer to obtain the right to sell any additional
          product in the Territory (whether or not similar to the Product).
          Douglas shall have sixty (60) days from the date that Senetek notifies
          Douglas that such additional product is to become available for sale
          in the Territory to deliver an offer to Senetek setting forth in
          reasonable detail the terms upon which Douglas would purchase, market
          and sell such product. If Senetek elects not to accept Douglas' offer
          (or if no offer is made within such period), Senetek shall be free to
          grant such rights to others on terms no better to such other party
          than those last offered by Douglas (or if Senetek has made a counter
          offer, on terms no better to such other party than those offered by
          Senetek to Douglas), or to exercise such rights itself, or any
          combination thereof, all in Senetek's sole and absolute discretion.

5.4       Extension of Territory to Australia: Upon registration of the Product
          in Australia Senetek shall give Douglas the option to extend its
          exclusive distribution rights for the Product to Australia. Douglas
          shall notify Senetek in writing within thirty (30) days from the date
          that Senetek notifies Douglas that the Product has been approved in
          Australia whether it wishes to extend the Territory to include
          Australia. If Douglas does wish to extend the Territory to include
          Australia the parties will in good faith negotiate any additional
          terms to this agreement to cover distribution of the Product by
          Douglas in Australia. If Douglas advises Senetek that it does not wish
          to distribute the Product in Australia or does not respond within the
          time period set out in this clause, Senetek shall be free to grant
          distribution rights in Australia to such other party as it determines.

5.5       Confidentiality: In the event that Senetek offers any additional
          product for sale in the Territory and Douglas does not accept such
          offer pursuant to clause 5.3, Douglas shall:

          (a)  maintain confidentiality in respect of any information and
               documentation provided to it by Senetek in respect of the
               product, and any associated trade marks and patents, on the terms
               set out in section 16; and

          (b)  promptly return to Senetek all documentation provided to Douglas
               in respect of the product.

5.6       Process for implementing changes: Where the parties agree that any
          additional product shall be added to this agreement, the parties shall
          prepare an amended list of Products (incorporating any additional
          trade marks used in connection with such additional product and the
          price for such product), which shall be deemed to be incorporated into
          this agreement, in substitution for the former list, once it has been
          signed by both parties. The parties shall then be bound from that time
          by the terms of this agreement in respect of the amended list of
          Products from the date of signing (except where the parties have
          specifically agreed in writing that such amendments shall take effect
          from a different date).

6.  REGISTRATION AND DOCUMENTATION

6.1       Documents to be obtained by Senetek: Senetek must, at its sole cost,
          obtain all necessary export

<PAGE>

          licenses and other documents and permits required to export the
          Product to Douglas for sale in the Territory.

6.2       Documents to be obtained by Douglas: Douglas must, at its sole cost,
          obtain all necessary import licenses and other documents and permits
          required to import the Product into the Territory.

6.3       Registration: Senetek shall register the Product with the appropriate
          authorities within the Territory, all such Product registrations to be
          at the cost of Senetek and (subject to clause 6.4) to be in the name
          of Senetek. In such circumstances:

          (a)  Douglas shall provide Senetek and any regulatory authorities
               directly involved in the registration of the Product with such
               reasonable assistance and information as is necessary to enable
               Senetek to obtain and maintain registration of the Product;

          (b)  Senetek agrees to reimburse Douglas for all reasonable expenses
               incurred by Douglas in providing such assistance and information;
               and

          (c)  Senetek shall provide Douglas with copies of any registration
               certificates or other evidence received upon registration of any
               of the Product, as well as any other information and
               documentation relating to the registration of the Product which
               Douglas may request from time to time.

6.4       Registration in name of Douglas: Where Senetek is not permitted
          pursuant to the relevant laws and regulations to register the Product
          in its own name, Douglas shall, with the prior written approval of and
          in cooperation with Senetek, carry out such Product registrations on
          behalf of Senetek, provided that:

          (a)  Douglas shall be entitled to reimbursement from Senetek in
               respect of any costs incurred pursuant to this clause 6.4; and

          (b)  Except for liability, claims and loss, damage, costs and expenses
               caused by the negligence of Douglas or any breach by Douglas of
               the terms of this Agreement (for which Douglas shall indemnify
               Senetek as provided in this clause (b>>, Senetek agrees to
               indemnify Douglas in respect of all liability, claims and loss,
               damage, costs and expenses (whether direct or indirect, and
               including all reasonable legal, accounting and other professional
               fees) awarded against, suffered or incurred by Douglas arising
               out of or in connection with the performance of its obligations
               under this clause 6.4.

7.  TERRITORY

7.1       Sale only to Douglas: Senetek must not sell or supply the Product in
          the Territory to any person other than Douglas and shall use all
          reasonable endeavours to prevent any unauthorised shipment of the
          Product in the Territory.

7.2       Sales outside Territory: Douglas shall not sell or permit the sale or
          delivery of the Product outside the Territory without the prior
          written consent of Senetek.

<PAGE>

Confidential Treatment Requested
--------------------------------

7.3       Referral of enquiries by Senetek: Senetek must refer to Douglas all
          enquiries which it receives from persons residing inside or outside
          the Territory relating to the purchase, use or resale of the Product
          in the Territory.

7.4       Referral of enquiries by Douglas: Douglas must not solicit orders
          outside of the Territory, and shall refer to Senetek all enquiries
          which it receives from persons residing inside or outside the
          Territory, relating to the purchase, use or resale of the Product
          outside the Territory.

8.  PLACEMENT OF ORDERS

8.1       Orders: Douglas shall order Product directly from Senetek by
          facsimile, confirmed in writing by mail. Douglas shall accompany each
          order with rolling twelve (12) months Product forecasts to be updated
          quarterly and delivered to Senetek at least thirty (30) days in
          advance of the period forecasted.

8.2       Minimum Sales Requirement: During the first year of the Term,
          Douglas shall sell [***]. For subsequent years Senetek and Douglas
          shall agree on the Minimum Sales Requirement based on the prior year's
          actual Net Sales, provided, however, that if the parties shall fail to
          agree on the Minimum Sales Requirement for any year after the first
          year by March 31 of such year, the Minimum Sales Requirement for such
          year shall be the prior year's Minimum Sales Requirement [***].
          Senetek may terminate this agreement in accordance with clause 16.3
          (b) if during any year of the Term Douglas fails to achieve the
          Minimum Sales Requirement with respect to such year.

8.3       Acceptance of orders: Senetek shall confirm acceptance of each order
          in writing within one week following receipt of the relevant order
          from Douglas.

8.4       Cancellation: Douglas may cancel an order at any time prior to
          acceptance by Senetek in accordance with clause 8.3.

9.  PAYMENT

9.1       Payment: Payment of all amounts under this agreement shall be made in
          accordance with the payment terms specified at the front of this
          agreement. All amounts are specified exclusive of any related taxes
          including any goods and services tax or other value added tax.

9.2       Withholdings: Douglas shall deliver to Senetek, as soon as is
          practicable after it has made any payment from which it is required by
          law to make any deduction, withholding or payment, a receipt, issued
          by the applicable taxing or other authorities evidencing the
          deduction, withholding or payment of all amounts required to be
          deducted, withheld or paid from such payment. If any such withholding
          or deduction is permitted to be recovered by Senetek, Douglas shall,
          at its expense, take all action necessary for Senetek to recover same.
          To the extent that any such withholding or deduction is not recovered
          by Senetek, Douglas shall pay the same to Senetek together within 90
          days of payment.

9.3       Set-off: Neither party shall set off against any payment due hereunder
          any amount claimed to be due from the other party, it being agreed
          that any disputes shall be resolved in the manner provided in section
          22.

10. DELIVERY

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

<PAGE>

10.1      Terms of delivery: Delivery shall be made in accordance with the terms
          specified at the front of this agreement and any terms (including any
          delivery date) specified in the relevant order submitted by Douglas.
          Senetek shall inform Douglas promptly when the first Products are
          ready for shipping and all approvals in New Zealand for the new
          manufacturing site are granted. The date of the first delivery shall
          be agreed upon by both parties. Time is of the essence in respect of
          any agreed date of delivery.

10.2      Risk: Risk of any loss or damage of or to the Product shall pass to
          Douglas in accordance with the terms of delivery specified at the
          front of this agreement.

10.3      Title: Title to the Products shall remain with Senetek until such
          Products have been sold by Douglas to a third party in accordance with
          the terms of this agreement.

11. WARRANTIES

11.1      Warranties: Senetek warrants that the Product will:

          (a)  conform to the Certificate of Assay accompanying each delivery;

          (b)  be of merchantable quality;

          (c)  be fit for the purposes specified in writing by Senetek;

          (d)  comply with any samples provided by Senetek to Douglas from time
               to time;

          (e)  comply with all descriptions, specifications and any other
               information provided by Senetek to Douglas from time to time in
               respect of the Product (whether contained in Product brochures or
               literature or on any Product packaging or labelling or as
               otherwise provided to Douglas); and

          (f)  comply with the guarantees set out in the Consumer Guarantees Act
               1993, and any other statutes, regulations, by-laws, standards,
               requirements and directions of any national or local authority
               having jurisdiction in relation to the sale or use of the Product
               in the Territory including, without limitation, all requirements
               relating to the registration of the Product.

11.2      Breach of warranty: If any of the Products fail to comply with the
          warranties contained in clause 11.1 at the time of delivery to Douglas
          then, provided that Douglas notifies Senetek of such failure within 30
          days from, and inclusive of, the date of receipt of the Products, then
          Douglas may, in its sole discretion and without prejudice to its other
          rights and remedies, require that Senetek replace the relevant Product
          (with all freight and other associated costs to be borne by Senetek).

12. INDEMNITY AND INSURANCE

12.1      Indemnification of Senetek: Douglas shall defend, indemnify, and hold
          harmless Senetek, its officers, agents, employees and affiliated
          companies from any loss, claim, action, damage, expense or liability
          (including reasonable defence costs and attorneys' and other
          professionals' fees) (collectively, "Claims') arising out of or
          related to a breach or alleged breach of any representation, warranty
          or covenant made by Douglas herein or the negligence of Douglas in the
          handling, possession, packaging, marketing, sale or other use of the
          Product, except insofar as

<PAGE>

          such Claims are related to or arise from any claim for which Senetek
          indemnifies Douglas under clause 12.2.

12.2      Indemnification of Douglas: Senetek shall defend, indemnify, and hold
          harmless Douglas, its officers, agents, employees and affiliated
          companies from any Claims arising out of or related to a breach or
          alleged breach of any representation, warranty or covenant made by
          Senetek herein, or Senetek's or its contract manufacturers'
          manufacture or handling of the Product to the point of delivery to
          Douglas, except insofar as such Claims are related to or arise from
          any Claim for which Douglas indemnifies Senetek under clause 12.1.

12.3      Insurance: Each party shall maintain at its expense commercial general
          liability insurance in a principal amount of not less than the
          coverage generally maintained by companies of similar size in the
          industry, insuring, in each case those matters for which each party
          indemnifies the other party in accordance with clause 12.2.

13. INTELLECTUAL PROPERTY RIGHTS

13.1      Ownership: Douglas acknowledges and agrees that all right, title and
          interest in and to any patents, trade marks, designs, confidential
          information, trade secrets, get-up and other intellectual property
          relating to:

          (a)  the Product;

          (b)  the Trade Marks; and

          (c)  all information provided by or on behalf of Senetek to Douglas
               under this agreement; shall belong to and remain with Senetek as
               its absolute property.

13.2      Infringement: Douglas shall promptly bring to the knowledge of Senetek
          any infringement or threatened infringement of any of Senetek's
          intellectual property or any passing-off of the Product. Any legal
          proceedings issued by Senetek in respect of such infringement or
          threatened infringement shall be conducted at Senetek's sole
          discretion and expense. If Senetek fails to take action in relation to
          any such infringement and Douglas considers in its sole discretion
          that the infringement adversely impacts on Douglas' ability to fully
          obtain the benefit of this agreement, Douglas may terminate this
          agreement either in its entirety or insofar as it applies to those
          Product affected by such infringement.

13.3      Indemnity: Without limiting anything contained in clause 12.2, Senetek
          shall indemnify Douglas and hold it harmless from and against all
          liability, claims, loss, damage, costs and expenses (whether direct or
          indirect, and including all reasonable legal, accounting and other
          professional fees) awarded against, suffered or incurred by Douglas
          arising out of or in connection with any claim that the purchase,
          distribution, sale or use of the Product infringes the intellectual
          property rights of any third party ("third party claim").

13.4      Third party claim: In relation to any third party claim:

          (a)  if either party becomes aware of a third party claim, it shall
               immediately inform the other party;

<PAGE>

          (b)  Senetek shall at its own cost and expense, conduct and/or settle
               all negotiations and litigation resulting from such claim; and

          (c)  Douglas shall afford all reasonable assistance with such
               negotiations and litigation, provided that Senetek shall
               reimburse Douglas for its staff costs and all other expenses
               incurred in providing such assistance.

13.5      Remedies: If at any time Douglas is prevented from importing, holding
          or selling any Product as a result of any third party claim, Senetek
          must, if requested by Douglas:

          (a)  obtain on behalf of Douglas the right to continue importing,
               holding or selling that Product which is the subject of a third
               party claim; or

          (b)  at Senetek's expense, modify the Product, or any packaging of the
               Product, so that it becomes non-infringing;

          provided that, if Douglas is not satisfied that Senetek has complied
          with its obligations under this clause within a reasonable period,
          Douglas may, without prejudice to any of its other rights and
          remedies, terminate this agreement in its entirety or insofar as it
          applies to the Product affected by the third party claim.

14. REPORTING

14.1      Reporting: If requested by Senetek from time to time, Douglas shall
          provide to Senetek a report setting out details of the volume and
          value of Product distributed and other information as Senetek may
          reasonably request including, without limitation, a list of
          prospective customers and performance forecasts.

15. CONFIDENTIALITY

15.1      Confidentiality: Each party shall treat as confidential, and not use
          or disclose to any person, any information relating to the terms of
          this agreement, the Product, or the other party and its business
          (including any information concerning the financial position of either
          party and its business, sales and technical operations or any
          information concerning the customers or suppliers of either party),
          provided that neither Douglas nor Senetek shall have any obligation
          under this clause concerning any information which is in the public
          domain, or which subsequently enters the public domain, through no
          fault, act or omission of the relevant party.

16. TERMINATION

16.1      Termination by either party: If:

          (a)  either party fails to comply with any of the terms of this
               agreement and does not remedy such breach (if the same is capable
               of remedy) within 30 days of receipt of a written notice from the
               other party requiring remedy;

          (b)  either party enters into any composition or arrangement with its
               creditors;

          (c)  either party does anything which would make it liable to be put
               into liquidation;

<PAGE>

          (d)  a resolution is passed or an application is made for the
               liquidation of either party; or

          (e)  a receiver or statutory or official manager is appointed over all
               or any of either party's assets;

          the other party may, without prejudice to any of its other rights or
          remedies, terminate this agreement.

16.2      Termination by Douglas: If Senetek obtains control of any competitor
          of Douglas, Douglas may, without prejudice to any of its other rights
          or remedies, terminate this agreement by notice in writing to Senetek.

16.3      Termination by Senetek: Senetek may, without prejudice to any of its
          other rights or remedies, terminate this agreement by notice in
          writing to Douglas:

          a)   if Douglas distributes a product that directly competes with the
               Product of Senetek in the Territory; or

          b)   if Douglas does not comply with the Minimum Sales Requirements as
               set forth under clause 8.2

17. EFFECT OF TERMINATION

17.1      Product held by Senetek on termination: Douglas shall have the option
          for a period of six months following the expiry or termination of this
          agreement to:

          (a)  fulfill any existing orders for Product received by Douglas on or
               prior to the date of expiry or termination of this agreement by
               the sale of Product held by Douglas at the date of expiry or
               termination; and

          (b)  in the case of termination by Douglas under clause 16.1. or 16.2.
               request Senetek to buy back any or all of the Product held by
               Douglas. The price payable shall be the invoice price to Douglas
               (together with any freight, insurance and transport charges,
               taxes and duties incurred by Douglas in respect of such Product).

17.2      Consequences arising: Upon the expiry or termination of this agreement
          all the rights and obligations of the parties under this agreement
          shall cease immediately, provided that the expiry or termination of
          this agreement shall not operate so as to affect clause 6.4(b), clause
          15.1 or clause 17.1 or any other provision of this agreement which is
          intended to continue after such expiry or termination.

17.3      Obligations of Douglas on termination: Following the expiry or
          termination of this agreement and upon the earlier of:

          (a)  the expiry of the six month period referred to in clause 17.1; or

          (b)  the supply by Douglas of the remainder of any Product held by it
               to its customers or to Senetek in accordance with clause 17.1;

          Douglas shall deliver to Senetek or, alternatively, destroy (in
          accordance with directions provided to it by Senetek) any and all
          copies (whether in digital form or hard copy) of any materials held

<PAGE>

Confidential Treatment Requested
--------------------------------

          by it relating to the Product which have been provided to it by
          Senetek (other than any information or material which is in the public
          domain through no fault on the part of Douglas).

18. FORCE MAJEURE

18.1      Force majeure: Neither party shall be liable for any act, omission or
          failure to perform any obligation under this agreement if such act,
          omission or failure arises or continues from any cause beyond the
          control of that party, and the relevant party could not take
          reasonable measures to prevent such act, omission or failure.

19. ASSIGNMENT

19.1      No assignment: Neither party may assign any of its rights or
          obligations under this agreement without the prior written approval of
          the other party, such approval not to be unreasonably withheld.

19.2      Change in effective control: Any transfer in the capital of either
          party or any holding company of either party without the approval of
          the other party which results in a change in the effective ownership
          or control shall, for the purpose of clause 19.1, be deemed to be an
          assignment of the rights granted under this agreement.

20. RELATIONSHIP OF THE PARTIES

20.1      Independent contractor: Douglas' relationship with Senetek during the
          Term shall be that of an independent contractor. Neither party has the
          power to assume or create any obligation on behalf of the other party
          except as expressly provided in this agreement. Douglas and Senetek
          are not partners or joint venturers. All contracts and other
          obligations undertaken by either party shall be undertaken by that
          party on its own behalf and shall not involve any financial or other
          responsibility on the part of the other party.

21.       LIABILITY 21.1 Mitigation: Each of the parties must take reasonable
          steps to mitigate any claim for any damages. 21.2 Consequential
          damages: Neither party shall be liable to the other for any indirect
          or consequential loss or damages (whether in contract or in tort,
          including negligence), including loss or damages comprising, or
          resulting from, loss of business or loss of profit, however caused.

21.3      Limitation of liability of Douglas: Under no circumstances shall
          Douglas or any of its affiliated companies have any liability arising
          from this agreement in excess of the highest aggregate amount paid by
          Douglas pursuant to this agreement over the two calendar years
          preceding any claim (or, if a claim shall be raised prior to the end
          of the second calendar year of the term, in excess of [***] of the
          average annualised amount received by Senetek during the Term. Senetek
          acknowledges and agrees that, but for the limitation of liability set
          forth in this clause, Douglas would not have entered into this
          agreement upon the terms set forth herein and that such limitation is
          a material part of this agreement

21.4      Limitation of liability of Senetek: Under no circumstances shall
          Senetek or its affiliated companies have any liability arising from
          this agreement in excess of the highest aggregate amount received by
          Senetek pursuant to this agreement over the two calendar years
          preceding any claim (or, if a claim shall be raised prior to the end
          of the second calendar year of the term, in excess of [***] of the
          average annualized amount received by Senetek during the Term. Douglas

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

<PAGE>

          acknowledges and agrees that, but for the limitation of liability set
          forth in this clause, Senetek would not have entered into this
          agreement upon the terms set forth herein and that such limitation is
          a material part of this agreement

22. DISPUTE RESOLUTION

22.1      Negotiation: The parties shall use their best endeavours to amicably
          resolve any dispute between them which may arise concerning the
          interpretation of this agreement or in relation to any matter arising
          under this agreement.

22.2      Mediation: If the parties cannot settle amicably and in good faith any
          dispute between them, either party may require such dispute to be
          referred to the mediation of a single mediator, or to more than one
          mediator if the parties so agree, to be appointed by the parties. The
          mediator shall conduct the mediation in accordance with the guidelines
          set by the parties.

22.3      Arbitration: If settlement is not reached within 60 days after
          commencing mediation, the dispute shall be settled by arbitration in
          accordance with the rules of conciliation and arbitration of the
          International Chamber of Commerce, and shall be held in the United
          Kingdom, with the official language of the procedure and arbitration
          to be the English language, and the award shall be final and binding
          upon the parties.

23. INTERNATIONAL SALE OF GOODS

23.1      Contracting out: The parties agree that the United Nations Convention
          on Contracts for the International Sale of Goods does not apply to the
          supply of any Product pursuant to this agreement.

24. NOTICES

24.1      Serving of notices: All notices required or authorised to be given or
          served under this agreement shall be in writing and may be given or
          served by personal service, prepaid registered mail or facsimile to
          the party at its address or facsimile number set out at the front of
          this agreement, or such other address or facsimile number as one party
          may have notified in writing to the other party.

25. GENERAL

25.1      Execution by counterparts and exchange by facsimile: This agreement
          may be executed by the parties in one or more counterparts. Such
          counterparts may be exchanged by facsimile (provided that each
          executed counterpart is transmitted in one complete transmission).
          Where there is an exchange of executed counterparts, each party shall
          be bound by the agreement notwithstanding that original copies of the
          agreement may not be exchanged immediately. The parties shall
          co-operate after execution of the agreement and exchange by facsimile
          to ensure that each party obtains an original executed copy of this
          agreement.

25.2      Governing law and jurisdiction: This agreement shall in all respects
          be deemed to be a contract made in England and the construction,
          validity and performance of such contract shall be governed by English
          law, and the parties shall submit to the non-exclusive jurisdiction of
          the courts of England.

25.3      Waiver: No delay, neglect or forbearance by either party in enforcing
          against the other any provision of this agreement will be a waiver, or
          in any way prejudice any right, of that party.

<PAGE>

25.4      Severability: If any clause or any part of any clause contained in
          this agreement is declared invalid or unenforceable, all other clauses
          or parts of clauses contained in this agreement will remain in full
          force and effect and will not be affected by invalidity for the term
          of this agreement, unless the commercial intentions of the parties are
          thereby frustrated.<PAGE>

Confidential Treatment Requested
--------------------------------

                                                                   Exhibit 10.56

                                LICENSE AGREEMENT

          This License Agreement (this "Agreement"), dated and effective as of
March 12, 2002 (the "Effective Date") is by and between SENETEK PLC, a British
public limited company ("Senetek"), with an office at 620 Airpark Road, Napa,
California 94588, U.S.A. and Enprani Co., Ltd., a company duly organized and
existing under the laws of the Republic of Korea ("Korea") ("Enprani") and
having a place of business at 441 Chunglim-dong, Chung-Ku, Seoul, Korea 100-791.

                                    RECITALS:

          A. Senetek has developed and holds Korea Patent No. 196660 (the
"Patent") relating to the formulations and use as a cosmetic product of certain
formulations containing Kinetin.

          B. Enprani wishes to acquire a license under the Intellectual Property
to manufacture, have manufactured, market, distribute and sell in the Market (as
defined below) skin care products containing [***] Kinetin by concentration,
pursuant to the terms and conditions of this Agreement.

          C. Senetek is willing to grant Enprani a license under the
Intellectual Property to manufacture, market, distribute and sell such products
in the Market, pursuant to the terms and conditions of this Agreement.

          D. The parties recognize and acknowledge that there is in effect a
Confidentiality and Non Use Agreement dated November 27, 2001 (the
"Confidentiality Agreement") pertaining to Enprani's use of Senetek's
confidential information relating to the Intellectual Property provided to
Enprani for certain evaluative purposes, which Confidentiality Agreement is
incorporated herein by reference.

          NOW, THEREFORE, in consideration of the premises and the mutual
covenants and undertakings set forth herein, and for other good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, the
parties agree as follows:

                                    ARTICLE I
                                   DEFINITIONS

          1.1    The Preamble and Recitals hereto are intended to be an integral
part of this Agreement, and the Preamble and Recitals hereto (including the
definitions set forth therein) are hereby incorporated by reference.

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

                                        1

<PAGE>

Confidential Treatment Requested
--------------------------------

          1.2 As used in this Agreement, the capitalized terms shall have the
following respective meanings:

          "Affiliate" with respect to Senetek or Enprani, any entity which,
directly or indirectly, owns or Controls, is owned or Controlled by, or is under
common ownership or common Control with Senetek or Enprani, as the case may be.
For purposes of this definition, ownership means the direct or indirect
beneficial ownership of more than 50% of the equity securities of the entity and
control means the power to direct the management or affairs of the entity.

          "Contract Year" shall mean a period from January 1 of a calendar year
through December 31 of a calendar year; provided that the first Contract Year
shall commence on the Effective Date and continue through December 31, 2002.

          "Improvement" shall mean any information, discovery, creation,
derivative work, or invention, whether or not patented or patentable or
copyrighted or copyrightable, based upon the Patent or the Know-How that is
developed or otherwise acquired after the Effective Date by Senetek or its
Affiliates.

          "Intellectual Property" shall mean (i) the Patents, (ii) Know-How,
(iii) Published Data, such as clinical trial data, in each case owned or
controlled by Senetek or its Affiliates relating to the Products (or any
Product) as of the Effective Date and necessary for the manufacture, marketing,
distribution and sale of the Products (or any Product) in the Market.

          "Know-How" shall mean such know-how, special knowledge, technical or
other information (including trade secrets and secret processes) such as
permeation and safety data, formulations, efficacy data and clinical trial
protocols, results and other information in connection with clinical trials,
whether or not patented or patentable, owned or controlled by Senetek or its
Affiliates as of the Effective Date specifically related to the development,
manufacture or use of the Products, but only to the extent any of the foregoing
is not subject to an agreement or commitment precluding Senetek from making it
available to Enprani.

          "Market" shall mean the markets which shall be licensed to Enprani
both on an exclusive and non-exclusive basis, as set forth in Section 2.1 of
this Agreement. Excluded are in all cases markets where medical products are
bought and/or sold (i.e., drugstores, hospitals, etc.), as well as the mass
market characterized by low price points. Furthermore, any retail or other
distribution outlets are excluded to the extent that they sell outside of The
Republic of Korea.

          "Packaging Requirements" shall have the meaning set forth in
Section 2.2.

          "Products" or "Product" shall mean, individually or collectively, any
or all cosmetic products containing a Kinetin concentration of up to and no more
than [***] by concentration.

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

                                        2

<PAGE>

          "Senetek Confidential Information" shall mean marketing, sales,
financial, scientific, and other non-public and/or proprietary information
concerning the products, projects, business and operations of Senetek including
the manufacture, use, or sale of the Products disclosed by Senetek to Enprani.

          "Territory" shall mean The Republic of Korea.

          "Unit" shall mean an individual container of Product for sale to an
individual end user (it being understood that each container of product
regularly sold together with a 10 ml and 8ml "gift," "bonus," or other bundles
of limited quantities and limited time, shall constitute a Unit).

                                   ARTICLE II
                         MANUFACTURING. SALE AND LICENSE

          2.1 Grant of License. Senetek hereby grants to Enprani an exclusive
license (except for the non-exclusive right of Osmotics Corporation in the same
distribution channel) and right in the Intellectual Property during the Term
solely to manufacture, market, distribute and sell the Products to any stores
and outlets, regardless of size, that exclusively deal with cosmetics and skin
care products (collectively referred to as "Cosmetics Specialty Stores" or
"Perfumeries") through any wholesaler and/or retailer within the Republic of
Korea ("the "License").Senetek further agrees to grant to Enprani a
non-exclusive license and right in the Intellectual Property during the Term to
manufacture, market, distribute and sell the Products in any and all other
markets in The Republic of Korea, whether wholesale or retail, and including,
without limitation, sales of Products via the Internet, TV Shopping channels or
similar market channels, but exclusive of the mass market in the Republic of
Korea targeting bargain shoppers, such as supermarkets, discount markets,
hypermarkets, convenience stores, and exclusive of drugstores and other outlets
where medical products are sold. For the purpose of this Agreement, the term
"Market" as used herein throughout this Agreement shall refer to the markets
which Enprani shall be licensed both on an exclusive and non-exclusive basis as
set forth in this Section.

          As soon as reasonably practicable after the Effective Date of this
Agreement, Senetek shall provide Enprani such of the Intellectual Property that
exists in written or electronic form that Senetek believes is necessary to
enable Enprani to manufacture the Products in accordance with the terms and
conditions of this Agreement.

          2.2. Packaging. All Product packaging and inserts (if any) (i) shall
state that "Manufactured And Sold Under License from Senetek PLC, Korea Patent
Number 196660", (ii) shall comply with applicable law and, (iii) shall be
otherwise acceptable to Senetek in its reasonable discretion (collectively, the
"Packaging Requirements").

                                        3

<PAGE>

Confidential Treatment Requested
--------------------------------

          2.3 Kinetin Raw Material. Enprani shall and shall cause its contract
manufacturers to purchase Kinetin from Senetek at Senetek's documented direct
cost, which is currently approximately [***]. In the case of Enprani purchasing
Kinetin from Senetek, Senetek agrees to deliver all Kinetin to Enprani or to a
designated address in Korea. Enprani shall have sole responsibility for
insurance, freight and other costs Senetek may incur, as well as duties, fees
and taxes imposed in Korea for such delivery, provided, however, that any taxes,
duties, fees, charges or assessments of any nature arising within the United
States and its subdivisions shall be borne by Senetek.

          2.4 Product Formulations. Senetek shall have the right (but not the
obligation) to analyze Enprani's formulations of the Products for compliance
with Senetek's efficacy and safety standards, which are as follows: Senetek
shall provide its assay method to Enprani to conduct testing of any and all
formulations produced and marketed by Enprani to insure that such formulations
have less than [***] systemic absorption with a time interval of [***], such
testing to utilize either mass spectrometry techniques or radioactive tracers.
Senetek is granted with the right of analysis of random samples prior to
Enprani's full production of the Product. Senetek reserves the right to update
or change testing procedures and shall promptly give Enprani a written notice
thereof. Senetek shall be afforded a period of fifteen (15) days upon receipt of
the data to provide its written approval or disapproval of such formulations
with written reasons for its decision. If no written response is received from
Senetek within fifteen(15) days upon receipt of the data, such formulation shall
be deemed approved. No approval of any formulation by Senetek shall be deemed an
endorsement of such formulation or a determination by Senetek that such product
is safe or effective, nor shall the same be implied by Enprani to any person or
entity. After the manufacture of the Product has commenced, Enprani shall report
to Senetek, from time to time, the analysis results for L random samples of the
Units manufactured with lots specified. Senetek shall have the right to audit,
at Senetek's expense, random samples of the product formulations once a year
during normal business hours, and more frequently if an audit reveals that
product formulation standards deviate from those standards stated herein.

          2.5 Enprani's Manufacturing Sites. Enprani (i) will provide Senetek
with access to any manufacturing sites operated by Enprani or its contract
manufacturers that produce Products and (ii) agrees to provide Senetek access to
and in conducting reasonable inspections of any manufacturing sites that
manufacture Products for Enprani solely for the purpose of ensuring compliance
with Senetek's standards in accordance with the following: (i) such
manufacturing site shall comply with cosmetic GMP standards and shall be free of
bacteria (i.e., subject to microbiological testing); and (ii) if necessary each
batch to be analyzed by Enprani to insure that the concentration is [***].
Senetek shall bear any costs and expenses (i.e., air fare, lodging, meals and
out-of-pocket expenses) incurred by Senetek's employees in connection with their
visit to Enprani's manufacturing sites and conducting inspections thereof,
except where such inspection uncovers material non-compliance with this
Agreement in which event Enprani shall reimburse Senetek for the reasonable
costs of inspection. Senetek shall not conduct such inspections more than once
per quarter; provided, however, that in any quarter in which Enprani fails
inspection and the following quarter, Senetek may conduct such inspections as it
deems reasonably necessary.

          2.6 Marketing Materials. Senetek shall have the right to pre-approve
Enprani's marketing materials to confirm that any representations are clinically
factual and the contents of the marketing materials are in compliance with, and
do not subject Senetek to unreasonable liability under all applicable laws
(including, but not limited to, the laws of the United States, the United
Kingdom and Korea). No such review or approval by Senetek shall constitute a
representation to Enprani or any other person or entity that such marketing
materials are accurate, in compliance with law or otherwise appropriate. No
marketing materials or other statements by Enprani or its Affiliates shall state
or imply any comparative advantages of Kinetin based on concentrations thereof.

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

                                        4

<PAGE>

Confidential Treatment Requested
--------------------------------

          2.7 No Other Rights. It is expressly understood that this Agreement
grants no rights to Enprani except those expressed rights set forth in Section
2.1. Without limiting the foregoing, it is understood and agreed that Enprani
shall (i) not sell or permit the sale of Products outside the Market specified
with respect thereto and (ii) not have any rights with respect to Improvements,
except as set forth in Section 2.8. below. Upon any termination of this
Agreement for any reason, all rights granted by this Agreement shall terminate
and Enprani shall have no right of any kind with respect to the Products,
Intellectual Property or Senetek's Improvements other than the right to complete
the sale of Products then lawfully in its possession subject to the payment of
royalties pursuant to Section 3.1.

          2.8 Improvements. During the Term, Enprani shall have a right of first
offer to obtain the right to sell in the Market any Improvement on a
non-exclusive basis; provided, however, that (x) such right of first offer shall
not apply with regard to products that are protected through patents or other
exclusivity as to, owned by, or vested in a third party and as to which Senetek
or its Affiliates have not acquired the right to grant marketing rights to
others, and (y) if Enprani fails to obtain any requisite regulatory approval to
sell such Improvement in the Market within twelve (12) months from the date the
parties execute an agreement governing the sale of such Improvement in the
Market, such agreement shall terminate and all such rights of Enprani with
respect to such Improvement shall revert to Senetek. Enprani shall have thirty
(30) days from the date that Senetek notifies Enprani that such an Improvement
is to or may become available for sale to deliver an offer to Senetek setting
forth in reasonable detail the terms upon which Enprani would purchase, market
and sell such product. If Senetek elects not to accept Enprani's offer (or if no
offer is made within such period), Senetek shall be free to grant such rights to
others, exercise such rights itself, or any combination thereof, all in
Senetek's sole and absolute discretion. Nothing in this Section 2.8 shall give
Enprani any rights with respect to any use or sale, including prior use or sale,
of Improvements outside the Market. Improvements remain the property of Senetek
unless, prior to commencement of any joint research and development efforts, the
parties agree that the results shall be jointly owned and the parties formally
agree in writing on the terms of such joint ownership.

                                   ARTICLE III
                            TERMS OF LICENSE AND SALE

          3.1 Royalty. In consideration of the licenses and rights set forth in
Section 2.1, Enprani shall pay a royalty to Senetek equal to [***] per Unit
sold. Exempt from royalty payment are a reasonable amount of up to 10 ml
consumer samples Enprani distributes free of charge in the Market. Royalties are
due and payable on any Product containing Kinetin and irrespective of the
validity of the Patent, and with respect to all sales in each Calendar Quarter
within thirty (30) days after the end of such Calendar Quarter. All such
payments shall be made by wire transfer either to [***], or to such other bank
as Senetek may from time to time advise. Royalty payments shall be accompanied
by a reasonably detailed accounting setting forth the basis upon which such
payment was calculated. Late payments shall be subject to a monthly processing
fee of one percent (1%) of the amount overdue or, if such amount is not
permitted by law, the maximum amount permitted by law. The timely payment of
royalties shall be a material term of this Agreement.

          3.2 Lump Sum Royalty Payment. Upon signing to this Agreement a royalty
lump sum payment by Enprani of [***] is due, it being understood that this [***]

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

                                        5

<PAGE>

Confidential Treatment Requested
--------------------------------

payment by Enprani shall have completely satisfied its obligation for the first
[***] Units of Products manufactured and sold by Enprani (excluding free gift
and consumer samples of up to 10 ml content), as well as the minimum sales
requirement of the first twelve months of the License and the corresponding
royalty payments therefore. Such royalty shall be paid as follows: [***]
upon signing of the Agreement; [***] upon any manufacturing of Products
(excluding consumer samples) by or for Enprani on or after the Effective Date,
however, not later than 30 days after the Effective Date.

          3.3. Minimum Sales Requirements. During the first two Contract Years,
Enprani shall sell not less than [***] Units during each Contract Year, and
during each subsequent Contract Year Enprani shall sell not less than [***]
Units per year (the "Minimum Sales Requirements"). In case the First Contract
Year consists of less than 12 calendar months, the Minimum Sales Requirement for
that First Contract Year shall be reduced by [***] Units for each full calendar
month missing. The Minimum Sales Requirement may be met with any combination of
Units (including line extensions and/or additional formulations) sold by Enprani
pursuant to this Agreement. In the event Enprani fails to meet the Minimum
Purchase Requirement, Senetek's sole remedy shall be termination of the
Exclusivity Right as per Section 7.2. below.

          3.4 Books and Records. Enprani shall keep books and records sufficient
the accuracy and completeness of its accounting referred to above, including
without limitation inventory, cost, sales, purchase and invoice records relating
to the Products or their manufacture, purchase and sale. Such books and records
shall be preserved for a period not less than six (6) years after they are
created during and after the Term of this Agreement. Notwithstanding the
foregoing and unless otherwise agreed or this is a dispute outstanding, all
books and records may be destroyed within six months from the effective date of
termination of this Agreement.

          3.5 Audit Right. Enprani shall take commercially reasonable steps
necessary so that Senetek may, within thirty (30) days of Senetek's request,
review portions of the books and records which contents are reasonably necessary
to verify the accuracy of Enprani's royalty payments at a single Korean
location. Such review may only be performed by a US or Korean licensed certified
public accountant designated by Senetek upon reasonable prior notice and during
regular business hours. Senetek shall conduct no more than two (2) reviews
during any Contract Year, provided, however, that if any such Audit reveals an
underpayment of royalties of more than 2%, Senetek may conduct such additional
Audits during that Contract Year and the immediately following Contract Year, if
any, as it reasonably deems necessary. Senetek shall also have the right to
audit Enprani's manufacturers of Products for the purpose of confirming the
quality of Products as well as quantity audits to support verification of the
accuracy of Enprani's royalty payments. The Senetek shall bear its own expenses
in connection with all audits under this Section 3.4, except that Enprani shall
pay for Senetek's expenses for any such audit which reveals that Enprani
underpaid its royalties by more than five (5) percent in any quarter.

          3.6 Market forecasts. Enprani shall provide Senetek with a rolling
twelve (12) month forecast of its anticipated sales of Products under this
Agreement to be updated quarterly, and delivered to Senetek at least thirty (30)
days in advance of the first day of the period required to be forecasted.

          *** Confidential portions of this materials have been omitted
        and filed separately with the Securities and Exchange Commission

                                        6

<PAGE>

          3.7 Notice of Non-Performance. Enprani shall notify Senetek in writing
promptly in the event Enprani is not in compliance with any material obligation
of Enprani under this Agreement.

                                   ARTICLE IV
                         MARKETING: REGULATORY APPROVALS

          Enprani shall be solely responsible for and shall take commercially
reasonable actions to register the Products for sale in Korea within the Market,
if and where so required, and obtain all other governmental approvals necessary
to sell the Products. Senetek shall provide commercially reasonable assistance
to Enprani in connection with, and shall promptly provide Enprani with all
reasonably necessary information within its possession, and shall use
commercially reasonable efforts to obtain and provide Enprani with all other
reasonably necessary information to permit the proper registration of, or
obtaining approval for the sale of, Products where required.

                                    ARTICLE V
                    REPRESENTATIONS. WARRANTIES AND COVENANTS

          Each of the parties hereto represents and warrants to the other that:
(i) it is duly organized, validly existing and in good standing in accordance
with the laws of its jurisdiction of organization; (ii) it has all requisite
legal and corporate power and authority to enter into and perform its
obligations under this Agreement: (iii) it has duly authorized the entry into
and performance of its obligations under this Agreement by all requisite
corporate actions; (iv) when executed by the presidents whose names appear on
the signature page hereof, this Agreement shall be a legal, valid and binding
obligation of such party enforceable in accordance with its terms, subject to
bankruptcy, insolvency and similar laws affecting creditors' rights generally
and general principles of equity; (v) its execution and delivery and performance
of its obligations under this Agreement do not breach, violate, conflict with or
contravene in any material respect (A) its organizational documents, (B) any
laws, rules, regulations, orders, judgments or decrees applicable to or binding
upon such party or its property, or (C) any other agreement, instrument,
mortgage, indenture, contract, license or other document to which it is a party
or by which it is bound; (vi) it has obtained all governmental and third party
consents and made all filings and notices required in connection with its
execution, delivery and performance of this Agreement, and all such consents,
filings and notices remain in full force and effect; and (vii) it will comply in
all material respects with all applicable laws, rules and regulations in the
conduct of its responsibilities and activities under this Agreement.

          Enprani hereby warrants and represents that it has no involvement in
the relationship between Senetek and OMP, Inc. and has no responsibility thereto
and that Senetek did never interfere in their former relationship with OMP, Inc.
and that Enprani terminated its relationship with OMP, Inc. independently from
Senetek and for reasons not connected with Senetek.

          Senetek warrants that as of the date of this Agreement, Senetek is not
aware of any actual or threatened suit by any third party claiming that
Senetek's licensing of the Intellectual Property in Korea infringes the rights
of such third party or claiming that any of the Intellectual Property is invalid
or unenforceable. Senetek further covenants that all Kinetin raw material
supplied by

                                        7

<PAGE>

or on behalf of Senetek to Enprani shall be consistent with the specifications
attached as Exhibit B, and the price of Kinetin raw material shall be at least
equal to the price offered to other licensees of Senetek in similar situations.

                                   ARTICLE VI.
                          NOTIFICATION OF INFRINGEMENT

During the Term, Enprani shall promptly advise Senetek in writing of any
infringement, imitation or act by third parties inconsistent with ownership or
any act of unfair competition by third parties (any of the foregoing shall be
referred to as an "infringement") relating to any of the Intellectual Property
wherever and whenever such infringement or act shall come to the attention of
such party.

                                  ARTICLE VII.
                              TERM AND TERMINATION

          7.1 Term. The term of is Agreement (the "Term" hall be five (5) years
from the Effective Date unless terminated earlier pursuant to the terms of this
Agreement. The Term of this Agreement shall be automatically renewed on an one
year basis unless either party gives the other party a written notice of
termination ninety (90) days before the end of the relevant Contract Year.

          7.2. Termination of Exclusivity. Senetek shall have the right to
terminate the exclusivity of the license granted to Enprani in this Agreement by
written notice to Enprani 90 days after the end of any Contract Year in which
Enprani failed to satisfy the Minimum Sales Requirement as set forth in Section
3.2 of this Agreement. In the event Enprani fails to provide sales data as
required by this Agreement or such sales data is inaccurate, Senetek shall have
a period of 90 days after the date accurate sales data are provided to make its
election, if applicable, under this Section 7.2.

          7.3 Termination for Cause. Each party shall have the right to
terminate this Agreement at any time upon written notice to the other in the
event if (i) the other party breaches any provision of this Agreement in a
material aspect and fails to cure such breach within 30 days after receipt of
written notice from the non-breaching party specifying such breach or (ii) the
other party is declared insolvent or bankrupt by a court of competent
jurisdiction, or a voluntary petition of bankruptcy is filed in any court of
competent jurisdiction by the other party, or the other party makes or executes
any assignment for the benefit of creditors.

          Senetek shall have the right to terminate this Agreement if Enprani's
payments under Section 3.1 are not received within fifteen (15) days of the date
they are due without providing notice, in which case Enprani shall cease all
manufacturing of, or causing to be manufactured, selling or distributing
Products, and shall provide an accounting with respect to the Calendar Quarter
for which payment was not received.

          Upon any termination of this Agreement for any reason, Enprani shall
have no right of any kind with respect to the Products, Intellectual Property or
Senetek's Improvements other than the right to complete the sale of Products
then lawfully in its possession subject to the payment of royalties pursuant to
Sections 3.1.

                                        8

<PAGE>

                                  ARTICLE VIII
               INDEMNIFICATION. INSURANCE AND LIMITS ON LIABILITY

          8.1 Indemnification by Enprani. Enprani shall defend, indemnify, and
hold harmless Senetek, its officers, agents, employees and affiliates from any
loss, claim, action, damage, expense or liability (including defense costs and
attorneys' fees) (collectively "Claims") arising out of or related to a breach
or alleged breach of any representation, warranty or covenant made by Enprani
herein, or the manufacture, handling, possession, marketing, sale or other use
of Products by Enprani, except insofar as such claims arise from Senetek's
negligence or breach of any representation, warranty or covenant made by Senetek
under this Agreement.

          8.2 Indemnification by Senetek. Senetek shall defend, indemnify, and
hold harmless Enprani, its officers, agents, employees and affiliates from any
Claims arising out of or related to (i) a breach or alleged breach of any
representation, warranty or covenant made by Senetek herein or (ii) any claim by
any person or entity other than Enprani or its Affiliates that the use of the
Intellectual Property in Korea by Enprani in accordance with the terms of this
Agreement infringes the rights of such person or entity, except with respect to
either (i) or (ii) insofar as such claims arise from Enprani's negligence or
breach of any representation, warranty or covenant made by Enprani in this
Agreement, or any Claims in connection with its relationship and/or contract
with OMP, Inc.; provided, however, that in the event of any claim of
infringement or in the event Senetek reasonably believes such a claim is likely
to be brought, then so long as Senetek shall undertake in writing to indemnify
and hold harnl1ess Enprani from and against any damages payable as a result of
infringement prior to the date of Senetek's indemnification undertaking, Senetek
may at its sole election either (a) obtain such rights at its expense as are
necessary to avoid such infringement, or (b) substitute non-infringing
technology of substantially equivalent functionality or (c) terminate this
Agreement upon written notice to Enprani and in the case of this clause (c), if
Enprani elects by written notice to Senetek to re-sell to Senetek its inventory
of Products, payment to Enprani of an amount equal to Enprani's actual direct
production cost of any number of up to six months sales (measured according to
the preceding six months sales) of Units held in inventory by Enprani.

          8.3 Insurance. Enprani shall maintain at its expense commercial
insurance as the solely responsible party for product liability coverage in
accordance with the relevant laws of Korea. Within thirty (30) days after the
date of this Agreement, Enprani shall furnish to Senetek certificates evidencing
its insurance, Senetek's designation as an additional insured, and such notice
requirement. Senetek may elect to suspend its performance under this Agreement
until any insurance required to be maintained by Enprani is in place and such
certificates of coverage are provided, and may thereafter suspend its
performance if it reasonably believes such insurance is not in place until
Enprani provides Senetek reasonable assurance that such coverage is in place
without any gap in coverage during the Term and will be maintained as required
by this Agreement.

          As promptly as practicable, and in any event within 180 days of the
date hereof, Senetek shall obtain at its expense commercial insurance for patent
related defense and damages expenses in amounts reasonable in relation to the
projected volume of sales of the Products by Enprani and such policy shall name
Enprani as an additional insured. Within 180 days after the date of this
Agreement, Senetek shall furnish to Enprani certificates evidencing its
insurance, Enprani's designation as an additional insured, and such notice
requirement. Enprani may elect to suspend its performance under this Agreement
until any insurance required to be maintained by Senetek is in place and such
certificates of coverage are provided, and may thereafter suspend its
performance if it reasonably believes such insurance is not in place until
Senetek provides Enprani reasonable assurance that such coverage is in place
without any gap in coverage during the Term and will be maintained as required
by this Agreement.

                                        9

<PAGE>

          8.4 No Consequential Damages. Neither party shall be liable to the
other for consequential damages, lost profits, injury to reputation or similar
claims, except for (a) claims that include consequential damages paid to
entities that are not Affiliates of an indemnified party or (b) consequential
damages incurred by Senetek as a result of Enprani selling Product outside of
the Market; Provided that nothing in this sentence shall be construed to limit
in any way Enprani's obligation to pay the royalties and other amounts due to
Senetek under this Agreement. UNDER NO CIRCUMSTANCES SHALL SENETEK OR ITS
AFFILIATES HAVE ANY LIABILITY ARISING FROM THIS AGREEMENT IN EXCESS OF THE
HIGHEST AGGREGATE AMOUNT PAID AS ROYALTIES OVER THE COURSE OF ANY THREE
CONSECUTIVE CONTRACT YEARS. Each party acknowledges and agrees that, but for the
limitations of liability set forth in this Section, the other party would not
have entered into this Agreement upon the terms set forth herein and that such
limitations are a material part of this Agreement. Notwithstanding the
foregoing, however, in the case where damages are incurred by Enprani as a
result of negligence or defect in the Patent or any other Intellectual Property
provided by Senetek, Senetek shall only be fully liable and compensate Enprani
for all direct damages.

          8.5 Recalls. In the event any Product(s) must be recalled from
distribution by reason of failure to meet any requirements of law or otherwise
(except as provided below), Enprani shall have the sole responsibility to effect
the recall and shall bear all expenses in connection therewith. Senetek shall
use its commercially reasonable efforts to cooperate with Enprani in
implementing any such recalls to the extent such cooperation is necessary to
effect the recall. Senetek shall be entitled to indemnification by Enprani for
the expense of such cooperation as set forth in Section 8.5. In the event recall
is solely the result of ingredients supplied by Senetek or its supply
subcontractors (other than Enprani or its supply subcontractors), Senetek shall
bear all such expenses.

          8.6 Survival of Obligations. Each party's obligations under this
Article VIII shall survive the expiration or termination of this Agreement.

          8.7 Limitation of Liability. Notwithstanding anything to the contrary
in this Agreement, in no event shall any party be liable to the other party or
any third party for any indirect, incidental, special or consequential damages
under any causes of any action, even if such party has been advised of the
possibility of such damages; provided that the liability limitation contained in
this Section 8.7 shall not apply to the parties' obligation to indemnify each
other against third party Claims pursuant to Sections 8.1 and 8.2.

                                   ARTICLE IX
                            CONFIDENTIAL INFORMATION

          9.1 Treatment of Prior Agreement. The Parties acknowledge that the
Confidentiality Agreement incorporated herein by reference pertains to use of
"Confidential Information" (as defined under such Confidentiality Agreement) for
certain evaluation purposes distinct from those uses contemplated hereunder and
addressed in this Article IX. Accordingly, the terms of such Confidentiality
Agreement shall not apply to uses of Senetek Confidential Information
contemplated in this Article IX.

          9.2 Non-disclosure of Senetek Confidential Information. With respect
to each disclosure, without the express written consent of Senetek, Enprani
shall not (a) use Senetek Confidential Information except to perform its
obligations under this Agreement, (b) disclose Senetek Confidential Information
to any person or entity (except to its employees and agents who reasonably
require the same for the purpose hereof and who are bound to Enprani by the same

                                       10

<PAGE>

obligations as to confidentiality), or (c) disclose Senetek Confidential
Information to any person or entity that competes with Senetek, unless such
disclosure is required by a governmental authority or by order of a court of
competent jurisdiction.

          9.3 Misuse of Enprani Confidential Information Prohibited. The parties
shall not misuse any information (including market and competitors' information)
obtained or acquired from each other during the Term of this Agreement, whether
they are indicated confidential or not.

          9.4 No Implied License. The furnishing of confidential information by
one party to the other shall not constitute any grant, option or license to the
other under any patent or other rights now or hereafter held by the furnishing
party.

          9.5 Survival. The provisions of this Article IX shall survive
termination of this Agreement and continue for a period five (5) years.

                                    ARTICLE X
                                  MISCELLANEOUS

          10.1 Governing Law. The validity, interpretation and performance of
this Agreement shall be governed and construed in accordance with the laws of
Switzerland (without application of conflict of laws principles thereof).

          10.2 Assignment. The parties may not assign this Agreement or any
rights or obligations hereunder without the prior written consent of the other
party, such written consent not to be withheld unreasonably; provided, however,
that no such assignment shall relieve the parties of their obligations under
this Agreement.

          10.3 Entire Agreement. This Agreement and the Confidentiality
Agreement constitute the full understanding of the parties and a complete and
exclusive statement of the terms of their agreement. All prior agreements,
negotiations, dealings and understandings, whether written or oral, regarding
the subject matter hereof, are hereby superseded and merged into this Agreement;
except for the Confidentiality Agreement between the parties.

          10.4 Amendments. This Agreement shall not be modified, rescinded or
waived except in writing signed by the party to be bound thereby.

          10.5 Notices. Any notice, request, approval or other document required
or permitted to be given under this Agreement shall be in writing and shall be
deemed to have been sufficiently given when delivered in person or by courier
service of established reputation to the President of the subject party at the
address for such subject party specified in the Preamble hereto or to such other
address as may be specified from time to time in a written notice to the other
party.

          10.6 Headings for Convenience. Section and article headings are
provided for convenience of the parties only and shall not be construed as a
part of this Agreement or a limitation on the scope of the particular sections
and articles to which they refer.

          10.7 Partial Invalidity. If any term or provision of this Agreement or
any application thereof shall be invalid or unenforceable, the remainder of this
Agreement or any other application of such term or provision shall not be
affected thereby.

                                       11

<PAGE>

          10.8 Counterparts. This Agreement may be executed in two or more
counterparts, each of which shall constitute an original and all of which
together shall constitute a single instrument.

          10.9 No Joint Venture. It is not the intent of the parties hereto to
form any partnership or joint venture. Each party shall, in relation to its
obligations hereunder, act as an independent contractor, and nothing in this
Agreement shall be construed to give either party the power or authority to act
for, bind or commit the other.

          10.10 Dispute Resolution; Binding Arbitration. Senetek and Enprani
agree to binding arbitration of any and all disputes or claims arising out of or
relating to this Agreement. Any arbitration shall be conducted in Switzerland,
unless otherwise agreed by the parties in writing. Each and any arbitration
shall be administered by a panel of three members under the auspices of the
International Chamber of Commerce in accordance with ICC's Rules on Conciliation
and Arbitration, as may be amended from time to time. All proceedings shall be
conducted in the English language. The decision or award of the panel shall be
final, binding and incontestable and may be used as a basis for judgment thereon
by any court of competent jurisdiction. Accordingly, there shall be no appeal to
any court or other authority from the decision of the arbitration panel, and the
parties shall not dispute nor question the validity of such decision or award
before any regulatory or other authority in any jurisdiction where enforcement
action is taken by the party in whose favor the decision or award is rendered,
except in the case of fraud.

          10.11 Exceptions to Binding Arbitration. Notwithstanding Section
10.10, (i) Senetek shall have the right to seek injunctive relief from any court
of competent jurisdiction in order to prevent immediate and irreparable injury,
loss, or damage, including, without limitation, in the event of termination of
this Agreement under Section 7.3 for the nonpayment of royalties, (ii) any and
all issues regarding the scope, construction, validity and enforceability of one
or more patents shall be determined in a court of competent jurisdiction under
the local patent laws of the jurisdictions having issued the patent or patents
in question, and (iii) ALL ACTIONS OR PROCEEDINGS CONTEMPLATED UNDER THIS
SECTION 10.11 SHALL BE LITIGATED IN COURTS HAVING SITUS WITHIN SWITZERLAND. THE
PARTIES HEREBY CONSENT AND SUBMIT TO THE JURISDICTION OF ANY COURTS LOCATED
WITHIN SWITZERLAND, AND EACH PARTY HEREBY IRREVOCABLY WAIVES ANY OBJECTION IT
MAY HAVE BASED UPON LACK OF PERSONAL JURISDICTION, IMPROPER VENUE OR FORUM NON
CONVENIENS.

          10.12 Attorney's Fees and Costs. In the event of any dispute
concerning or arising out of this Agreement, the prevailing party shall be
entitled to recover its reasonable attorneys' fees and costs.

          10.13. Force Majeure. The performance or observance by either party of
any obligations of such party under this Agreement may be suspended by it, in
whole or in part and without liability, to the extent (and only to the extent)
any of the following prevents such performance or observance: (a) Act of God,
war, riot, uprising, fire, explosion, accident, flood, sabotage, lockout or
injunction, (b) national defense requirement; (e) compliance with governmental
laws, regulations, rules, orders or actions; or (f) any other cause (whether
similar or dissimilar) beyond the reasonable control of such party; provided,
however, that the party so prevented from complying with its obligations (i) has
taken commercially reasonable steps to avoid the effects of such Force Majeure
event and (ii) shall immediately notify in writing the other party thereof and
such party so prevented shall exercise diligence in an endeavor to remove or
overcome the cause of such inability to comply.

          To evidence their agreement, the parties have executed this Agreement
as of the date hereto affixed.

                                       12

<PAGE>

SENETEK PLC

BY   /s/ FRANK J. MASSINO
  -----------------------------------
     FRANK J. MASSINO, ITS PRESIDENT         DATE: March 12, 2002

ENPRANI CO., LTD.

BY   /s/ HAE-KWAN, KIM
  -----------------------------------
     HAE-KWAN, KIM, ITS PRESIDENT            DATE: March 12, 2002

                                       13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00049-of-00352.parquet"}]]